Business Insider
My Markets Watchlist
Markets Stocks

Alkermes PLC Stock , ALKS

29.09 -0.23 -0.78%
03:59:59 PM EDT 6/20/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/20/2025 the closing price of the Alkermes PLC share was $29.32 on BTT. Compared to the opening price on Friday 06/20/2025 on BTT of $29.39, this is a drop of 0.22%. Alkermes PLC's market capitalization is $3.92 B by 164.90 M shares outstanding.

Alkermes Stock Snapshot

24.94
Bid
100.00
Bid Size
33.26
Ask
100.00
Ask Size
6/20/2025
Date
3:59 PM
Time
56,746.00
Volume
29.32
Prev. Close
29.39
Open
4.80 B
Market Cap in USD
164.90 M
Number of Shares
164.90 M
Total Number of Shares
28.92
Day Low
29.60
Day High
29.09
22.90
52 Week Low
36.44
52 Week High
29.09
0.00
Dividend in USD
0.00
Dividend Yield
13.26
P/E Ratio
97.74
Free Float in %
2.17
EPS in USD
9.03
Book Value per Share in USD
2.60
Cash Flow per Share in USD

Historical Prices for Alkermes

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Alkermes Analyst Data

Total Analysts: 30
Buy Ratings: 15 Neutral Ratings: 14 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 25.00 Median: 37.90 Highest: 52.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Alkermes Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
06/17/25 UBS
Upgraded to Buy $42
05/28/25 Needham & Company, LLC
Maintained Buy $45
05/02/25 RBC Capital Markets
Maintained Hold $40
05/02/25 Baird Patrick & Co
Maintained Buy $41
04/28/25 UBS
Maintained Hold $33
03/27/25 Deutsche Bank
Maintained Buy $52
03/13/25 RBC Capital Markets
Maintained Hold $40
03/04/25 UBS
Upgraded to Hold
02/14/25 Goldman Sachs
Maintained Buy $32
02/13/25 H.C. Wainwright & Co.
Maintained Hold $46
02/11/25 Deutsche Bank
Maintained Buy $40
07/25/24 Cantor Fitzgerald
Maintained Buy $48
07/25/24 J.P. Morgan
Maintained Hold $32
07/25/24 Baird Patrick & Co
Maintained Buy $38
07/25/24 H.C. Wainwright & Co.
Maintained Hold $37
07/15/24 J.P. Morgan
Maintained Hold $31
06/04/24 H.C. Wainwright & Co.
Maintained Hold $35
05/23/24 Cantor Fitzgerald
Maintained Buy $48
05/02/24 H.C. Wainwright & Co.
Maintained Hold $35
04/19/24 H.C. Wainwright & Co.
Maintained Hold $35
04/09/24 Jefferies & Company Inc.
Maintained Buy $50
04/01/24 Piper Sandler
Maintained Buy $39
03/19/24 Baird Patrick & Co
Maintained Buy $37
02/20/24 UBS
Downgraded to Sell $25
02/16/24 Piper Sandler
Maintained Buy $39
01/02/24 Bank of America Merrill Lynch
Maintained Hold $29
11/20/23 J.P. Morgan
Maintained Hold $33
10/27/23 Piper Sandler
Maintained Buy $35
10/26/23 Mizuho
Maintained Buy $35
10/24/23 Evercore
Upgraded to Buy
10/17/23 UBS
Maintained Hold $31
07/27/23 H.C. Wainwright & Co.
Maintained Hold $34

Alkermes Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 1,386 1,439 1,409 1,459 1,594
Dividend 0.00 0.00 0.00 0.00 0.00
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
EPS 1.69 1.78 1.56 1.54 1.99
P/E Ratio 17.21 16.35 18.67 18.87 14.60
EBIT 200 226 175 204 291
EBITDA 309 287 244 303 421
Net Profit 195 212 175 223 283
Net Profit Adjusted 294 302 264 291 375
Pre-Tax Profit 255 271 224 264 338
Pre-Tax Profit Reported 233 204 138 195 312
EPS (Non-GAAP) ex. SOE 1.80 1.73 1.36 1.21 -
EPS (GAAP) 1.15 1.13 0.91 1.20 1.73
Gross Income 1,189 1,247 1,240 1,314 1,476
Cash Flow from Investing -72 -39 -40 -43 -44
Cash Flow from Operations 338 380 365 427 631
Cash Flow from Financing -40 0 0 -17 -17
Cash Flow per Share 2.04 1.90 1.62 1.83 2.10
Free Cash Flow 350 176 137 - -
Free Cash Flow per Share - - - - -
Book Value per Share 10.80 12.36 13.78 15.85 18.04
Net Debt -798 -1,087 -1,205 -2,126 -2,452
Research & Development Exp. 315 333 354 336 318
Capital Expenditure 39 37 36 34 36
Selling, General & Admin. Exp. 657 664 688 708 771
Shareholder’s Equity 1,775 2,077 2,367 2,788 3,260
Total Assets 2,313 2,839 2,960 3,425 3,878
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 12 12 12 12
Average Estimate - 0.382 USD 0.469 USD 1.690 USD 1.779 USD
Year Ago - 0.543 USD 0.566 USD 2.219 USD -
Publish Date - 7/23/2025 10/22/2025 - -
Revenue Estimates
No. of Analysts - 15 15 15 15
Average Estimate - 348 USD 356 USD 1,386 USD 1,439 USD
Year Ago - 399 USD 378 USD 1,558 USD -
Publish Date - 7/23/2025 10/22/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 1,557.63 1,663.41 1,111.80 1,173.75 1,038.76 1,170.95 1,094.27
Change of sales in % -6.36 49.61 -5.28 13.00 -11.29 7.01 21.13
Gross profit on sales 1,305.50 1,365.08 845.32 926.02 805.89 936.20 840.79
Gross profit on sales change in % -4.36 61.49 -8.71 14.91 -13.92 11.35 24.36
Operating income 420.64 414.12 -142.27 -29.29 -112.43 -75.48 -93.43
Operating income change in % 1.57 - -385.76 73.95 -48.95 19.21 36.83
Income before tax 443.75 421.52 -167.30 -39.31 -96.54 -197.06 -126.97
Income before tax change in % 5.27 - -325.64 59.28 51.01 -55.20 11.38
Income after tax 372.14 519.16 -158.27 -48.17 -110.86 -196.62 -139.31
Income after tax change in % -28.32 - -228.57 56.55 43.62 -41.14 11.80

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 590.59 933.54 920.23 911.90 882.75 719.96 653.72
Long-term liabilities per share 0.77 2.48 2.57 2.72 2.79 2.08 2.02
Equity 1,464.98 1,202.69 1,043.75 1,112.58 1,066.98 1,085.44 1,171.29
Equity change in % 21.81 15.23 -6.19 4.27 -1.70 -7.33 -2.62
Balance sheet total 2,055.57 2,136.22 1,963.98 2,024.48 1,949.73 1,805.40 1,825.01
Balance sheet total change in % -3.78 8.77 -2.99 3.83 7.99 -1.07 1.55

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 9.21 9.80 6.80 7.29 6.54 7.46 7.05
P/E ratio (year end quote, basic EPS) 13.26 13.23 - - - - -
P/E ratio (year end quote, diluted EPS) 13.26 13.23 - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 71.27 56.30 53.14 54.96 54.72 60.12 64.18
Debt ratio in % 28.73 43.70 46.86 45.04 45.28 39.88 35.82

Alkermes Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Nichols Christian Todd 06/09/2025 3,334.00 86,208.00 31.09 Sell No
Nichols Christian Todd 06/08/2025 3,333.00 89,542.00 31.95 Sell No
Wright Christopher I 06/07/2025 793.00 23,013.00 31.71 Sell No
Wright Christopher I 06/07/2025 3,301.00 23,806.00 n/a Buy No
Lurker Nancy 05/30/2025 1,924.00 10,705.00 30.61 Sell No
Wilson Frank Anders 05/30/2025 1,924.00 31,084.00 30.61 Sell No
Wright Christopher I 05/30/2025 1,924.00 20,505.00 30.61 Sell No
snyderman nancy lynn MD 05/30/2025 1,924.00 10,728.00 30.61 Sell No
MCKEON BRIAN P 05/30/2025 1,924.00 33,869.00 30.61 Sell No
Cooke Shane 05/30/2025 4,175.00 103,744.00 30.61 Sell No
LAURENCIN CATO T 05/30/2025 1,924.00 29,102.00 30.61 Sell No
GAYNOR RICHARD 05/30/2025 1,924.00 31,084.00 30.61 Sell No
Wilson Frank Anders 05/30/2025 8,013.00 33,008.00 n/a Buy No
Lurker Nancy 05/30/2025 8,013.00 12,629.00 n/a Buy No
snyderman nancy lynn MD 05/30/2025 8,013.00 12,652.00 n/a Buy No
Wright Christopher I 05/30/2025 8,013.00 22,429.00 n/a Buy No
MCKEON BRIAN P 05/30/2025 8,013.00 35,793.00 n/a Buy No
LAURENCIN CATO T 05/30/2025 8,013.00 31,026.00 n/a Buy No
GAYNOR RICHARD 05/30/2025 8,013.00 33,008.00 n/a Buy No
Cooke Shane 05/30/2025 8,013.00 107,919.00 n/a Buy No
Lurker Nancy 04/10/2025 558.00 1,765.00 27.00 Sell No
Lurker Nancy 04/10/2025 901.00 4,616.00 27.00 Sell No
Lurker Nancy 04/10/2025 2,323.00 2,323.00 n/a Buy No
Lurker Nancy 04/10/2025 3,752.00 5,517.00 n/a Buy No
Parisi Samuel Joseph 02/27/2025 1,938.00 7,717.00 34.00 Sell No

Alkermes Dividend Calendar

Date Name Dividend *yield Currency
2024 Alkermes PLC 0.00 0.00 USD
2023 Alkermes PLC 0.00 0.00 USD
2022 Alkermes PLC 0.00 0.00 USD
2021 Alkermes PLC 0.00 0.00 USD
2020 Alkermes PLC 0.00 0.00 USD
2019 Alkermes PLC 0.00 0.00 USD
2018 Alkermes PLC 0.00 0.00 USD
2017 Alkermes PLC 0.00 0.00 USD
2016 Alkermes PLC 0.00 0.00 USD
2015 Alkermes PLC 0.00 0.00 USD
2014 Alkermes PLC 0.00 0.00 USD
2013 Alkermes PLC 0.00 0.00 USD
2012 Alkermes PLC 0.00 0.00 USD
2011 Alkermes PLC 0.00 0.00 USD
2010 Alkermes PLC 0.00 0.00 USD
2009 Alkermes PLC 0.00 0.00 USD
*Yield of the Respective Date

Alkermes Calendar

Event Estimate Info Date
Earnings Report 0.382 USD Q2 2025 Earnings Release 07/23/2025
Earnings Report 0.469 USD Q3 2025 Earnings Release 10/22/2025
Earnings Report 0.579 USD Q4 2025 Earnings Release 02/12/2026
Earnings Report 0.338 USD Q1 2026 Earnings Release 05/06/2026

Alkermes Past Events

Event Actual EPS Info Date
Annual General Meeting 2.170 USD Annual General Meeting 05/21/2025
Earnings Report 0.130 USD Q1 2025 Earnings Release 05/01/2025
Earnings Report 0.880 USD Q4 2024 Earnings Release 02/12/2025
Earnings Report 0.550 USD Q3 2024 Earnings Release 10/24/2024
Earnings Report 0.530 USD Q2 2024 Earnings Release 07/24/2024
Annual General Meeting 2.100 USD Annual General Meeting 05/31/2024
Earnings Report 0.210 USD Q1 2024 Earnings Release 05/01/2024
Earnings Report 0.660 USD Q4 2023 Earnings Release 02/15/2024
Earnings Report 0.280 USD Q3 2023 Earnings Release 10/25/2023
Earnings Report 1.380 USD Q2 2023 Earnings Release 07/26/2023
Earnings Report -0.250 USD Q1 2023 Earnings Release 04/26/2023
Earnings Report -0.170 USD Q4 2022 Earnings Release 02/16/2023
Earnings Report -0.390 USD Q3 2022 Earnings Release 11/02/2022
Earnings Report -0.180 USD Q2 2022 Earnings Release 07/27/2022
Annual General Meeting -0.300 USD Annual General Meeting 07/07/2022
Earnings Report -0.220 USD Q1 2022 Earnings Release 04/27/2022
Earnings Report 0.010 USD Q4 2021 Earnings Release 02/16/2022

Alkermes Profile

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.